Abstract 1580
Background
Brain metastases (BMs) account for a relatively large proportion of patients with metastatic non-small cell lung cancer (NSCLC) both at the time of diagnosis and during the course of disease, which is a major cause leading to a significant increase in cancer-related mortality for NSCLC patients. We aimed to build a novel risk classification system to predict overall survival (OS) of patients presenting with BMs at the first diagnosis of NSCLC.
Methods
Data on NSCLC patients with BMs was extracted from the SEER database between 2010 and 2013. All cases were randomly divided into the training cohort and validation cohort (7:3). Cox regression was performed to select the independent predictors of OS. A nomogram was established for predicting 6-, 12- and 18-month OS. The prognostic performance of nomogram was evaluated using concordance indexes (C-indexes), calibration curves, and decision curve analyses (DCAs). All statistical analysis was performed with R software.
Results
According to the multivariate Cox regression of the training set, the following variables were contained in the nomogram prognostic model: age, marital status, sex, race, primary site, histological type, T stage, N stage, metastatic pattern, whether received radiotherapy and chemotherapy. The nomogram displayed good accuracy in predicting 6, 12 and 18 months OS. The C-indexes of training set and validation set were 0.729 and 0.723, respectively. The calibration curves showed excellent consistency between the actual results and the nomogram prediction, and the DCAs exhibited great clinical utility of the model. A new risk classification system based on nomogram scores was introduced to classify NSCLC patients with BMs into three subgroups. In the training cohort, the median OS of patients in the low-, intermediate- and high-risk groups was 11.0 months (95% confidence interval [CI] 10.3–11.7), 5.0 months (95% CI 4.6–5.4), and 2.0 months (95% CI 1.9–2.1), respectively.
Conclusions
We established a risk stratification system based on nomogram scores to predict the OS of patients presenting with BMs at initial diagnosis of NSCLC. These predictive models can act as auxiliary tools to guide treatment strategies and prognostic evaluation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5054 - Inhibition of Rspo-Wnt pathway Facilitates Checkpoint Blockade Therapy by anti-RSPO3 antibody (DBPR117)
Presenter: John Hsu
Session: Poster Display session 1
Resources:
Abstract
3305 - A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumors
Presenter: Jürgen Krauss
Session: Poster Display session 1
Resources:
Abstract
5353 - Phase 1/2 Study of 9-ING-41, a small molecule selective Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancies or Solid Tumors
Presenter: Benedito Carneiro
Session: Poster Display session 1
Resources:
Abstract
3946 - Trial in progress: a Phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumors (NCT03447314).
Presenter: Aaron Hansen
Session: Poster Display session 1
Resources:
Abstract
3449 - Radiographic Phenotyping to Identify Intracranial Disseminated Recurrence in Brain metastases Treated With Radiosurgery Using Contrast-enhanced MR Imaging
Presenter: CheYu Hsu
Session: Poster Display session 1
Resources:
Abstract
4553 - Association between TP53 mutations and efficacy of Osimertinib for brain metastasis from EGFR-mutant lung cancer
Presenter: Lijuan Chen
Session: Poster Display session 1
Resources:
Abstract
4942 - Response assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: a comparison of RECIST 1.1, RANO and iRANO criteria
Presenter: Emilie Le Rhun
Session: Poster Display session 1
Resources:
Abstract
3529 - Management of multiple brain metastases by Staged SRS focusing on utmost risk lesions
Presenter: shaoqun Li
Session: Poster Display session 1
Resources:
Abstract
5315 - Whole brain radiotherapy plus simultaneous in-field boost versus whole brain radiotherapy plus fractionated stereotactic radiotherapy for multiple brain metastases of non-small cell lung cancer
Presenter: Lu Li
Session: Poster Display session 1
Resources:
Abstract
1116 - 3D based texture analysis serving as potential diagnostic factor in discriminating primary central nervous system lymphoma from metastatic brain tumors: A preliminary study
Presenter: Wen Guo
Session: Poster Display session 1
Resources:
Abstract